Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Ariad Pharmaceuticals
So what: The company didn't release any news, but the stock has been actively traded and options are pointing to bullish signs. Option volume is nearly 8:1 calls to puts, indicating a very bullish bet by investors, and stock volume is more than double the three-month average.
Now what: Investors are placing bets ahead of Ridaforolimus Phase 3 SUCCEED trial data, which should be released early next year. There doesn't seem to be any letup from the run Ariad has been on since mid-November, when the stock started to climb sharply higher. Option volume would indicate there is still some momentum left in the stock as the SUCCEED trial nears an end.
Interested in more info on Ariad Pharmaceuticals? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.